IP Library Granted Patent US 10,596,202
Granted Patent B2
US 10,596,202 · App. 15/865,220 · Granted Mar 24, 2020

Compositions and methods for treating and preventing tissue injury and disease

Inventors: Dale R. Peterson (Carlsbad, CA); Ralph-Heiko Mattern (Romona, CA); Kevin L. Ohashi (Jamaica Plain, CA); Lael J. Pickett (White Bear Lake, MN); Glen Gong (San Carlos, CA); Mohammad A. El-Kalay (Carlsbad, CA)
Assignee: MicroVascular Tissues, Inc.
A61K35/44A61K35/12A61L27/3625A61L27/3687A61L27/3691A61L27/3834A61L27/54C12N5/0653A61L2300/41A61L2300/412A61L2430/02A61L2430/06A61L2430/10A61L2430/34A61L2430/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,202
App. No.
15/865,220
Granted
Mar 24, 2020
Kind
B2
Abstract

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Claims (8)

1. A method for the treatment of nerve damage, comprising administering a therapeutic agent to a subject in need thereof, wherein the therapeutic agent comprises enriched, nonviable multipotent cells, wherein the nerve damage comprises peripheral neuropathy.

2. The method of claim 1 , wherein the multipotent cells are sterilized by irradiation.

3. The method of claim 1 , wherein the multipotent cells have been isolated from microvascular tissue.

4. The method of claim 1 , wherein the multipotent cells have been enriched by removal of extraneous tissue and culturing the multipotent cells.

5. The method of claim 1 , wherein the multipotent cells have been enriched by culturing the multipotent cells.

6. The method of claim 1 , wherein administering the therapeutic agent comprises injection or surgical application to the region of damaged nerves.

7. The method of claim 1 , wherein administering the therapeutic agent comprises systemic injection.

8. The method of claim 1 , wherein the therapeutic agent is a powder, gel or ointment applied topically near the site of nerve damage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2020
From: PETERSON, DALE R.; MATTERN, RALPH-HEIKO; OHASHI, KEVIN L.; PICKETT, LAEL J.; GONG, GLEN G.; EL-KALAY, MOHAMMAD
To: MICROVASCULAR TISSUES, INC.
Reel/Frame 051668/0746 →
Continuity (4)
Continuation In Part 15633311 · Jun 26, 2017
Continuation 14429511
Provisional Application 61703203 · Sep 19, 2012
Related Publication 20180161379A1 · Jun 14, 2018
Cited By (2)
US 12,364,716 US 12,551,509